These data position survodutide as a leading glucagon/GLP-1 receptor dual agonist that could be a game-changer for people living with MASH and clinically significant fibrosis. The full trial results were also published in The New England Journal of Medicine
Colon Cancer Patients Who Took GLP-1s Experienced Lower Death Rates The study analyzed health data from more than 6,900 patients within University of California health systems who had been diagnosed with colon cancer
Application of liposomes in dermatology Liposomal formulations have shown considerable promise in treating numerous dermatological problems, such as infections, inflammatory disorders, and neoplastic lesions, by boosting medication penetration, improving bioavailability, and minimising systemic side effects
Notably, certain synthetic and natural agents exhibit the capacity to disrupt glutathione dynamics and enzyme function
While no protein shake is specifically formulated for semaglutide users, certain products align well with the clinical considerations outlined above